South African regulators warn against recalled iDEXIS GLP-1 products

South African health regulators have warned the public and clinicians against continued use, prescribing, dispensing, or stockholding of recalled iDEXIS semaglutide, tirzepatide, and combined semaglutide/tirzepatide products. The warning is documented by the government-run SAnews service and SAHPRA’s official rapid-alert register.

Which products are covered

The July 10 joint warning from the South African Pharmacy Council, Health Professions Council of South Africa, and South African Health Products Regulatory Authority names three iDEXIS product groups: semaglutide, tirzepatide, and semaglutide/tirzepatide mixtures. SAHPRA’s Rapid Alert System lists the action as Case 99.

This is more precise than describing the action as a recall of generic ‘Ozempic copies.’ The warning concerns named iDEXIS compounded products, including tirzepatide and a mixed-product category—not every semaglutide product in South Africa.

What regulators told practitioners

• Stop continued use, prescribing, dispensing, and stockholding of the recalled iDEXIS products.
• Healthcare professionals who continue handling them may face disciplinary action under applicable medicines law.
• The agencies characterized continued use as a serious patient-safety risk.
• SAHPRA’s rapid-alert process is designed to remove unregistered products and investigate substandard or falsified medicines.

What remains unclear

• The public notice does not provide batch counts or the total quantity distributed.
• It does not report whether a specific adverse event triggered the action.
• The short government report does not provide laboratory results for the recalled products.
• Patients need product-specific advice from a pharmacist, prescriber, or the regulator rather than relying on broad brand comparisons.

The central safety message is straightforward: people should not continue using the named recalled iDEXIS products, and practitioners should follow the regulator’s recall instructions. Anyone uncertain about a product’s identity or registration should contact a licensed pharmacist or SAHPRA.